Extract
Cytomegalovirus (CMV) is a betaherpesvirus, the impacts of which are well known to clinicians providing post-transplant cystic fibrosis care. Lung transplant recipients have the highest risk of any solid-organ transplant for CMV reactivation and ganciclovir resistance [1, 2]. Furthermore, CMV reactivation increases the risk of chronic lung allograft dysfunction. However, even in general populations, CMV seropositivity is associated with adverse outcomes including cognitive impairment, frailty, heart disease and all-cause mortality [3–5]. How CMV may contribute to disease is not evident but many streams of evidence suggest CMV replication in inflamed sites contributes to exaggerated inflammation and tissue injury [6].
Abstract
Of cystic fibrosis (CF) patients referred for lung transplant consideration, those who are cytomegalovirus (CMV) IgG+ at referral are 8 years younger than seronegatives, suggesting CMV may have a pathogenic role in CF lung disease http://ow.ly/iSQf30nAxxl
Footnotes
Author's contributions: M.D. Parkins was primarily responsible for the data collection and record maintenance. Statistical analyses were performed by R. Somayaji and M.D. Parkins. M.D. Parkins was responsible for the creation of the initial draft of the manuscript. All authors contributed to development of the final manuscript. M.D. Parkins is the guarantor of this work.
Conflict of interest: M.D. Parkins reports grants from CF Canada, CIHR Canada, Gilead Sciences and the Alberta and NWT Lung Association, outside the submitted work.
Conflict of interest: K.J. Ramos reports grants from the National Institutes of Health, Cystic Fibrosis Foundation and CHEST Foundation, outside the submitted work.
Conflict of interest: C.H. Goss reports grants from the Cystic Fibrosis Foundation, European Commission and NIH (NHLBI, NIDDK and NCRR), during the conduct of the study; and personal fees from Gilead Sciences and Novartis, grants from the NIH and FDA, and serving as the US lead in a phase 2 trial of a novel therapy for cystic fibrosis for Boehringer Ingelheim, outside the submitted work.
Conflict of interest: R. Somayaji reports grants from CF Canada, CIHR Canada and Alberta Innovates, outside the submitted work.
- Received September 14, 2018.
- Accepted January 10, 2019.
- Copyright ©ERS 2019
INDIVIDUALS
Log in using your username and password
LIBRARY USERS
Log in through your institution
Purchase access
CONTACT US
If you have any questions about the ERS publications website, please contact journals@ersnet.org
